Varian Acquires Aspekt Solutions, Strengthening Advanced Oncology Solutions Offering

Acquisition of Aspekt Solutions expands Varian's medical physics and dosimetry services, building on Varian's commitment to providing a holistic approach to cancer care.

Varian, a Siemens Healthineers company, announced today that it has acquired Aspekt Solutions, a leading provider of medical physics, dosimetry, and strategy consultation services. The acquisition of Aspekt Solutions will expand Varian’s Advanced Oncology Solutions (AOS) offerings and increase the ability to address the rising demand for customized services and standardized care delivery.

Cancer care is evolving rapidly, and providers face numerous challenges, including the rising cost of care, technological complexity, and a shortage of skilled personnel. While navigating these challenges, cancer centers strive to meet several competing objectives in clinical quality, operational efficiency, and technology utilization. Through AOS, Varian offers tailored engagements that harness the power of technology and combine it with professional support from world-class experts with diverse clinical and operational experience. These teams collaborate with cancer centers to help them realize their unique goals for expanding, upgrading, or standardizing operations while implementing global best practices in cancer care.

“Through our AOS offerings, we’ve been leading the way in melding innovative technology with clinical expertise to help address these challenges,” commented Chuck Lindley, Vice President of AOS, at Varian. “With Aspekt Solutions, we can support more oncology centers with a holistic approach to addressing today’s challenges while also preparing for the fast-evolving future of cancer care.”

“As part of Varian, we are confident that we will have more opportunities to empower clinicians and patients around the world,” added Brian Pellegrini, CEO of Aspekt Solutions. “We are excited to continue our mission of bringing together the best team of physicists, dosimetrists, and consultants in the industry and partnering with clients to support and extend their existing programs and prepare them for the future. Our immediate focus will be on ensuring that the transition is as smooth as it is beneficial for customers and Aspekt Solutions employees.”

SourceVarian

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”